Hepatic arterial floxuridine for colorectal liver metastases
Author Information
Author(s): C Fordy, C Glover, MM Davies, TG Allen-Mersh
Primary Institution: Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK
Hypothesis
Hepatic arterial floxuridine might be a useful second-line treatment in patients whose colorectal liver metastases have become resistant to systemic fluorouracil/folinic acid.
Conclusion
Hepatic arterial floxuridine achieved a 14% partial response and a 26% disease stabilization rate in patients with systemic fluorouracil-resistant colorectal liver metastases.
Supporting Evidence
- HAI achieved a 14% partial response rate in patients with systemic fluorouracil-resistant colorectal liver metastases.
- 26% of patients experienced disease stabilization after treatment.
- The median duration of response was 7 months.
- Serum CEA levels significantly decreased after 4 months of treatment.
Takeaway
This study looked at a treatment called hepatic arterial floxuridine for patients whose cancer didn't respond to regular chemotherapy, and it helped some patients feel better for a while.
Methodology
Patients received hepatic arterial cannulation and were treated with a regimen of continuous floxuridine and dexamethasone, followed by monitoring of liver metastasis volume and quality of life.
Potential Biases
There may be biases due to the non-randomized nature of the study and variations in treatment protocols across centers.
Limitations
The study may have underestimated the quality of life deficits and did not account for variations in systemic chemotherapy treatment across different centers.
Participant Demographics
Median age was 56.8 years, with 19 females and 16 males.
Statistical Information
P-Value
0.007
Statistical Significance
p=0.007
Want to read the original?
Access the complete publication on the publisher's website